Navigation Links
Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
Date:12/8/2011

eutical company developing novel oncology compounds that target cancer stem cells (CSCs) and tumor bulk. Stemline is currently developing two clinically active compounds, both of which have demonstrated durable complete responses (CRs) and an overall survival (OS) benefit in Phase I/II studies. SL-401 has completed a multicenter Phase I/II trial in patients with advanced acute myeloid leukemia (AML) where it has demonstrated single agent activity, including two durable CRs and an OS benefit, in heavily pretreated patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. SL-401 is also currently being tested in additional indications including chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). The Company's second clinical program, SL-701, has demonstrated single agent activity including durable tumor responses, which includes CRs, multiple partial responses (PRs) and an OS benefit, in Phase I/II trials of adult patients with refractory or recurrent high grade glioma and pediatric patients with malignant glioma. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at www.stemline.com.

Stemline Contact:
Mark Jacobson
Associate Director, Business Development
Stemline Therapeutics, Inc.
Tel: 212-584-5747
Email: mjacobson@stemline.com

This announcement contains forward-looking statements relating to Stemline's business, which are based on the Company's current expectations concerning future d
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
2. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
3. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
6. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
7. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
8. Nile Therapeutics, Inc. Completes $2.5 Million Private Placement
9. Cell Therapeutics, Inc. (CTI) to Present at Bio Europe Spring 2011
10. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
11. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... assessment to be added to the, ... 28 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or "Company") ... on activities as well as an interim progress ... is conducting a human Phase 1b/2a clinical trial ...
... Sigma-Aldrich (Nasdaq: SIAL ) today announced the global ... provides a novel and powerful approach to RNAi screening in ... http://www.sigma.com/esirna ) incorporates a pool of hundreds of ... designed to eliminate the trial and error approach of identifying ...
... Techne Corporation,s (Nasdaq: TECH ) consolidated net ... to $27.6 million or $.74 per diluted share compared with ... ended March 31, 2008. For the nine months ended ... $79.9 million or $2.10 per diluted share compared with $76.3 ...
Cached Biology Technology:Resverlogix Provides Quarterly Update 2Resverlogix Provides Quarterly Update 3Resverlogix Provides Quarterly Update 4Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 2Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 3Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 2Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 3Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 5Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 6Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 7
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws ... efficiency are piloting the North American and European automotive ... accidents growing, gesture recognition systems that are intuitive and ... mark in the industry. New analysis ... Gesture Recognition Market in Europe ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... clever trick for overcoming sleep deprivation. Sam Ridgway from the ... to send half of their brains to sleep while the ... to be able to remain continually vigilant for sounds for ... colleagues from San Diego and Tel Aviv wonder whether the ...
... May 1, 2009 As people become more educated, studies ... lower in calories but higher in nutrients. They also pay ... of the Journal of the American Dietetic Association , ... and food costs of a sample of 164 adults in ...
... plants are constantly confronted with adverse environmental conditions, lowering ... use specialized signals, called stress hormones, to sense difficult ... Of the various stress hormones, abscisic acid ... last 30 years as the key hormone that helps ...
Cached Biology News:Dolphins maintain round-the-clock visual vigilance 2People of higher socioeconomic status choose better diets -- but pay more per calorie 2Synthetic chemical offers solution for crops facing drought 2Synthetic chemical offers solution for crops facing drought 3
Request Info...
Request Info...
... ml CELLection Dynabeads (4.5 m) coated with ... antigen EpCAM and DNase Releasing Buffer. ... epithelial tumour cells directly from blood, bone ... be enriched from bone marrow. Enriched cells ...
PHOTOMAN DIRECT COPY CAMERA, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: